AVITA Medical, Inc. (RCEL)
9.92
-0.14
(-1.39%)
USD |
NASDAQ |
Aug 24, 16:00
9.92
0.00 (0.00%)
After-Hours: 20:00
AVITA Medical Debt to Equity Ratio : -1.742 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.742 |
| March 31, 2026 | -2.077 |
| December 31, 2025 | -2.766 |
| September 30, 2025 | -6.717 |
| June 30, 2025 | -3.459 |
| March 31, 2025 | -9.642 |
| December 31, 2024 | 10.22 |
| September 30, 2024 | 3.732 |
| June 30, 2024 | 1.885 |
| March 31, 2024 | 1.374 |
| December 31, 2023 | 0.8645 |
| September 30, 2023 | 0.0437 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0248 |
| March 31, 2023 | 0.0241 |
| December 31, 2022 | 0.0108 |
| September 30, 2022 | 0.0126 |
| June 30, 2022 | 0.0139 |
| March 31, 2022 | 0.015 |
| June 30, 2021 | 0.0137 |
| March 31, 2021 | 0.0147 |
| December 31, 2020 | 0.032 |
| September 30, 2020 | 0.0356 |
| June 30, 2020 | 0.034 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Halozyme Therapeutics, Inc. | 14.95 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 47.78M |
| Total Liabilities (Quarterly) | 75.62M |
| Shareholders Equity (Quarterly) | -27.84M |
| Current Ratio | 0.4132 |
| Net Debt Paydown Yield | -0.69% |